Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 23 · below the Ichimoku cloud · RSI 34 · MACD below its signal
| 2.61 | Previous month high | +42.62% |
| 2.61 | 52-week high | +42.62% |
| 2.04 | Previous week high | +11.48% |
| 1.94 | R3 (classic) | +6.19% |
| 1.94 | Previous month low | +6.01% |
| 1.91 | R2 (classic) | +4.19% |
| 1.87 | Previous day high | +2.19% |
| 1.87 | R1 (classic) | +2.09% |
| 1.86 | Previous week low | +1.64% |
| 1.83 | Pivot | +0.09% |
| 1.83 | Price now | |
| 1.79 | Previous day low | −1.91% |
| 1.79 | S1 (classic) | −2.00% |
| 1.76 | S2 (classic) | −4.01% |
| 1.72 | S3 (classic) | −6.10% |
| 1.33 | 52-week low | −27.32% |
None of the 29 investors followed here reported a position in IKT in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a IKT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.8 | 36.7 | -18.0 | 12.5 | -7.4 | 16.0 | 7.4 | 6.0 | -11.0 | -10.9 | −10.7% | ||
| 2025 | -30.2 | 1.3 | -4.8 | 3.2 | -11.1 | -3.0 | -19.0 | 13.9 | -10.0 | -9.3 | 3.4 | 34.9 | −36.9% |
| 2024 | 137.5 | -28.4 | 0.0 | -31.9 | 25.2 | -34.2 | 16.5 | -0.7 | -7.1 | 94.6 | 15.4 | 11.3 | +155.9% |
| 2023 | 41.2 | 4.7 | -11.0 | -15.0 | 23.1 | -12.5 | -30.2 | -20.2 | -30.8 | -36.3 | 5.9 | 35.4 | −57.7% |
| 2022 | -4.8 | -24.3 | 39.6 | -27.0 | -15.2 | -18.9 | 14.4 | 12.9 | -5.2 | -15.2 | -21.6 | -17.4 | −66.0% |
| 2021 | -3.5 | 0.6 | -10.3 | -13.0 | 2.3 | -47.7 | -18.9 | 4.4 | -19.8 | 4.7 | 0.5 | -26.5 | −78.7% |
| 2020 | — |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 29, 2026 | Berman Dennis NDirector | Conversion of Exercise of derivative security at price 1.26 per share. | 21.9K | $27.54K |
| Nov 20, 2025 | Sands Capital Life Sciences Pulse Fund Ii, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.45 per share. | 2.07M | $3.00M |
| Feb 20, 2025 | Munshi Amit DDirector | Stock Award(Grant) at price 0.00 per share. | 57.3K | — |
| Oct 20, 2024 | Munshi Amit DDirector | Purchase at price 2.22 per share. | 365K | $810.30K |
| Oct 20, 2024 | Kush ArvindDirector | Purchase at price 2.22 per share. | 145K | $321.90K |
| Oct 20, 2024 | Bellini RobertoDirector | Purchase at price 2.22 per share. | 1.46M | $3.24M |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Buy / hold / sell counts